EZH2 and prostate carcinoma: Moreover, EZH2 can induce epithelial mesenchymal transition (EMT) and increase the metastatic potential of prostate cancer cells by downregulating DAB2IP, a tumour suppressive Ras GTPase-activating protein (RasGAP)30.